Loading...
Market
What will be the outcome of Concentra's acquisition proposal for Kezar by end of 2024?
3
Resolution / Starting Odds
Accepted • 25%
Rejected • 25%
Revised Offer • 25%
No Decision • 25%
Official announcements from Kezar Life Sciences or Concentra Biosciences
Story
Kezar Life Sciences Receives $1.10/Share Proposal from Concentra Biosciences, Shares Up 4.7%
Oct 10, 2024, 12:34 PM
Kezar Life Sciences (KZR) has received an unsolicited, non-binding acquisition proposal from Concentra Biosciences. The offer includes a cash payment of $1.10 per share and a contingent value right (CVR). This proposal follows Tang Capital Management's disclosure of a 9.9% stake in Kezar as of October 1, 2024, indicating strong investment confidence in the company’s pipeline of therapies for immune-mediated and oncologic disorders. Tang Capital is the controlling stockholder of Concentra Biosciences. Kezar's shares have risen by 4.7% in premarket trading following the news.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by up to 20% • 25%
Decrease by up to 20% • 25%
Decrease by more than 20% • 25%
Acquisition completed • 25%
Acquisition failed • 25%
Acquisition delayed • 25%
Acquisition withdrawn • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Volatile • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Regulatory approval • 25%
Shareholder approval • 25%
Financial considerations • 25%
Strategic realignment • 25%
Successful acquisition at €11 per share • 25%
Acquisition at a different price • 25%
Acquisition fails • 25%
Acquisition postponed • 25%
Acquisition completed • 25%
Acquisition delayed • 25%
Acquisition canceled • 25%
Other outcome • 25%
Less than $1B • 25%
$1B to $2B • 25%
$2B to $3B • 25%
More than $3B • 25%
Yes • 50%
No • 50%
Q4 2023 • 25%
Q1 2024 • 25%
Q2 2024 • 25%
Q3 2024 • 25%